Table 3.

Plasma nevirapine concentrations (median and range) in different groups of children

Groups	n	Trough (μg/mL)	n	2 h (μg/mL)
Sex
female	41	3.6 (0.6–12.6)	39	5.0 (1.5–16.3)
male	47	3.7 (0.1–10.1)	48	6.0 (1.6–18.9)
Dose
<300 mg/m2/day	40	3.3 (1.3–10.9)	40	5.3 (2.1–18.9)
≥300 mg/m2/day	48	4.1 (0.1–12.6)	47	6.2 (1.5–16.3)
Drug formulations, d4T:3TC:NVP
6:30:50	24	3.5 (0.1–10.9)	22	5.2 (1.5–13.5)
10:40:70	25	3.3 (1.2–10.1)	27	5.3 (1.6–18.9)
30:150:200	39	4.5 (0.6–12.6)	38	6.1 (1.6–16.3)
HAZ score
stunted (<−2 HAZ)	55	3.6 (0.6–12.6)	55	5.3 (1.6–14.3)a
normal	33	3.9 (0.1–10.0)	32	6.1 (1.5–18.9)
WAZ score
underweight (<−2 WAZ)	51	3.7 (0.6–12.6)	53	5.6 (1.6–18.9)
normal	37	3.2 (0.1–10.9)	34	5.6 (1.5–16.3)
Age
≤3 years	17	2.5 (0.1–10.9)a	14	4.2 (1.5–13.5)a
>3 years	71	4.0 (0.6–12.6)	73	5.7 (1.6–18.9)

^aP < 0.05.